AU3762801A - Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor - Google Patents

Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor

Info

Publication number
AU3762801A
AU3762801A AU37628/01A AU3762801A AU3762801A AU 3762801 A AU3762801 A AU 3762801A AU 37628/01 A AU37628/01 A AU 37628/01A AU 3762801 A AU3762801 A AU 3762801A AU 3762801 A AU3762801 A AU 3762801A
Authority
AU
Australia
Prior art keywords
clarythromycin
metronidazole
erythromycin
treatment
pump inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37628/01A
Other languages
English (en)
Inventor
Andrew Ilchyshyn
Ian Andrew Whitcroft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00301951A external-priority patent/EP1133987A1/de
Application filed by Individual filed Critical Individual
Publication of AU3762801A publication Critical patent/AU3762801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU37628/01A 2000-03-09 2001-03-09 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor Abandoned AU3762801A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00301951A EP1133987A1 (de) 2000-03-09 2000-03-09 Behandlung von entzündlichen Dermatosen mit Erythromycin oder Clarithromycin, Metronidazol und einem Wasserstoffpumpehemmer
EP00301951 2000-03-09
US18896100P 2000-03-10 2000-03-10
US60188961 2000-03-10
PCT/GB2001/001047 WO2001066117A1 (en) 2000-03-09 2001-03-09 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor

Publications (1)

Publication Number Publication Date
AU3762801A true AU3762801A (en) 2001-09-17

Family

ID=26073033

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37628/01A Abandoned AU3762801A (en) 2000-03-09 2001-03-09 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor

Country Status (4)

Country Link
EP (1) EP1263445A1 (de)
AU (1) AU3762801A (de)
CA (1) CA2413923A1 (de)
WO (1) WO2001066117A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049716A1 (en) * 2001-12-13 2003-06-19 Ranbaxy Laboratories Limited Stable topical formulation of clarithromycin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
IS3990A (is) * 1992-04-24 1993-10-25 Ab Astra Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
CA2180535C (en) * 1994-01-05 2004-03-23 Lindberg, Per Lennart A method for treatment of psoriasis, by omeprazole or related compounds
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
JPH10158172A (ja) * 1996-11-29 1998-06-16 Takeshi Azuma 肝性脳症治療剤又は肝性脳症予防剤
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components

Also Published As

Publication number Publication date
WO2001066117A1 (en) 2001-09-13
EP1263445A1 (de) 2002-12-11
CA2413923A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
GB2369494B (en) Method of preventing semiconductor layers from bending and semiconductor deviceformed thereby
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2002349705A1 (en) Azole compound and medicinal use thereof
AUPR406501A0 (en) Treatment of vault prolapse
AU2001240978A1 (en) Glycogen phosphorylase inhibitor
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
AU2002342354A1 (en) Ureteral drainage device
AU2002356977A1 (en) Aggressive prefetch of address chains
MXPA03004459A (es) Inhibidores de imidazol y benzimidazol caspasa y usos de los mismos.
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU2002346622A1 (en) Electrosphincterotome and manometry catheter
AU2002345959A1 (en) Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
AU2002349241A1 (en) Method of chemical of ionization at reduced pressures
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
WO2001054476A8 (en) Multi-party electronic transactions
AU2001281771A1 (en) Brand positioning within electronic personal devices
AU2002338730A1 (en) Pressure reducer
AU2002365066A1 (en) Mutant proteinase inhibitors and uses thereof
AU2001241498A1 (en) Matrix metalloproteinase inhibitors and uses thereof
AU3762801A (en) Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
AU2001245414A1 (en) Treatment of allergies
AU2001271400A1 (en) Bioelastomer nanomachines and biosensors
ITBO20000744A0 (it) Riduttore planetario multistadio
AU2002306045A1 (en) Ferroelectric devices and method relating thereto
AU2001282349A1 (en) Fluid treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase